exogen
administr
human
albumin
use
primarili
volum
expans
albumin
account
oncot
pressur
plasma
proprieti
albumin
includ
carri
hydrophob
substanc
antioxid
activ
antithrombot
effect
antiinflammatori
effect
endotheli
stabil
recent
publish
review
articl
highlight
properti
indic
exogen
albumin
administr
albumin
compar
normal
salin
patient
acut
ischem
stroke
follow
intern
studi
albumin
dose
gkg
maximum
volum
ml
equival
volum
normal
salin
administ
within
hour
symptom
onset
studi
termin
earli
futil
find
differ
primari
endpoint
neurolog
outcom
day
patient
treat
albumin
experienc
pulmonari
edema
rr
ci
short
breath
rr
ci
symptomat
intracrani
hemorrhag
within
hour
rr
ci
random
multicent
openlabel
albio
trial
compar
albumin
administ
maintain
serum
albumin
level
gdl
crystalloid
solut
studi
patient
sever
sepsi
found
differ
mortal
day
despit
differ
volum
fluid
administ
two
group
first
day
studi
net
fluid
balanc
lower
arteri
blood
pressur
higher
albumin
group
compar
crystalloid
group
cohort
studi
patient
bleed
peptic
ulcer
compar
follow
three
group
patient
normal
serum
albumin
patient
serum
albumin
less
gdl
patient
serum
albumin
less
gdl
treat
day
g
albumin
everi
hour
rebleed
significantli
lower
patient
normal
serum
albumin
compar
group
hypoalbuminemia
durat
hospit
versu
day
p
patient
treat
albumin
compar
untreat
patient
low
albumin
crystalloid
versu
colloid
resuscit
includ
albumin
subject
systemat
review
metaanalysi
studi
demonstr
possibl
benefit
albumin
crystalloid
mortal
sepsi
patient
odd
ratio
mortal
ci
statist
signific
patient
sever
sepsi
british
metaanalysi
trial
patient
demonstr
mortal
benefit
albumin
crystalloid
signal
harm
albumin
plasma
expans
follow
paracentesi
patient
cirrhot
liver
diseas
associ
less
circulatori
dysfunct
ci
statist
signific
effect
mortal
hyponatremia
encephalopathi
readmiss
renal
dysfunct
statist
signific
differ
death
ci
renal
dysfunct
ci
found
cirrhot
patient
infect
metaanalysi
includ
studi
patient
debat
resuscit
crystalloid
versu
colloid
albumin
effect
lung
pathophysiolog
histor
perspect
evid
review
recent
articl
author
conclud
despit
theoret
benefit
resuscit
albumin
prevent
respiratori
dysfunct
anaphylact
shock
due
human
albumin
found
fibrinogen
erythrocyt
concentr
report
male
patient
gener
anesthesia
prolaps
mitral
valv
replac
skin
prick
intraderm
test
use
confirm
reaction
albumin
administr
human
albumin
furosemid
compar
furosemid
alon
review
metaanalysi
studi
hour
combin
albumin
furosemid
result
increas
ml
ci
clinic
decis
transfus
patient
base
sole
singl
hemoglobin
number
accord
american
cancer
societi
blood
transfus
lifesav
howev
without
risk
substanti
overutil
transfus
base
avail
hemovigil
program
blood
transfus
cite
one
top
five
overutil
therapeut
procedur
unit
state
establish
hemovigil
program
start
year
ago
franc
initi
variou
monitor
system
blood
transfus
committe
laid
foundat
nation
hemovigil
system
import
factor
consid
evalu
patient
transfus
suggest
hemovigil
system
includ
goal
therapi
prior
experi
transfus
individu
riskbenefit
analysi
institut
experi
nation
databas
suggest
restrict
blood
transfus
approach
increasingli
implement
best
practic
accord
red
cross
blood
servic
organ
blood
product
transfus
carri
potenti
risk
caus
side
effect
typic
risk
incid
fairli
small
organ
classifi
reaction
acut
occur
within
hour
transfus
delay
occur
hour
posttransfus
common
acut
immunolog
reaction
hemolyt
aborh
mismatch
occur
patient
febril
nonhemolyt
transfus
reaction
may
affect
patient
latter
treat
antipyret
consider
includ
mild
allerg
reaction
urticaria
patient
affect
seriou
sever
reaction
anaphylaxi
much
lower
incid
urticaria
treat
antihistamin
diphenhydramin
steroid
report
delay
immunolog
reaction
includ
posttransfusionrel
purpura
transfusionassoci
graft
versu
host
diseas
tagvhd
report
rare
patient
weaker
immun
system
suscept
tagvhd
reaction
notabl
commonli
cite
transfus
reaction
occur
transfusionrel
acut
lung
injuri
trali
incid
transfusionassoci
circulatori
overload
taco
less
report
incid
reaction
report
adult
pediatr
patient
popul
recent
retrospect
canadian
studi
sought
evalu
similar
differ
adult
pediatr
patient
present
symptom
trali
recent
transfus
total
case
trali
report
n
occur
children
retrospect
trial
demonstr
symptomat
present
trali
patient
popul
similar
overlook
although
number
small
appear
differ
present
outcom
adult
children
trali
stratifi
pediatr
patient
age
group
author
note
children
present
trali
either
teenag
less
old
potenti
conclud
two
pediatr
patient
popul
higher
risk
human
leucocyt
antigen
hla
one
clinic
implic
pathway
trali
suspect
occur
unit
kingdom
unit
state
demonstr
benefit
exclud
plasma
collect
femal
donor
mean
reduc
incid
trali
recipi
result
reduct
approxim
half
twothird
trali
incid
fatal
almost
disappear
previou
studi
conclud
pregnanc
come
increas
probabl
hla
alloimmun
form
respons
appear
longlast
alloantibodi
tend
present
frequent
femal
given
birth
least
two
children
report
indic
preval
hla
antibodi
donor
popul
men
women
hemosiderosi
iron
overload
anoth
potenti
complic
transfus
incid
iron
overload
typic
increas
number
transfus
retrospect
chart
analysi
determin
preval
risk
factor
liver
toxic
associ
transfus
relat
iron
overload
trio
pediatr
oncolog
patient
recent
publish
author
studi
also
report
experi
iron
chelat
therapi
ict
singl
major
risk
factor
trio
number
transfus
preval
greater
patient
receiv
transfus
four
patient
trio
elev
liver
function
test
receiv
chelat
therapi
studi
author
conclud
signific
decreas
serum
ferritin
level
improv
liver
function
test
observ
seriou
advers
effect
iron
chelat
therapi
aggress
blood
transfus
may
affect
longterm
mortal
one
hypothesi
chang
immun
function
potenti
increas
risk
infect
risk
certain
cancer
author
sought
find
differ
liber
transfus
strategi
receiv
blood
transfus
maintain
hemoglobin
level
gl
gdl
higher
vs
restrict
transfus
strategi
receiv
blood
transfus
hemoglobin
level
lower
gl
gdl
symptom
anemia
patient
enrol
studi
randomli
assign
ratio
liber
transfus
strategi
restrict
transfus
strategi
followup
durat
year
patient
die
howev
longterm
mortal
differ
significantli
liber
transfus
strategi
death
restrict
transfus
strategi
death
hazard
ratio
ci
p
find
support
idea
blood
transfus
lead
longterm
immunosuppress
sever
enough
affect
longterm
mortal
rate
anoth
studi
provid
interest
insight
uniqu
patient
popul
otherwis
candid
blood
transfus
time
sever
anem
retrospect
studi
analyz
clinic
outcom
patient
year
older
could
transfus
least
one
hemoglobin
measur
gdl
surgeri
major
patient
selfidentifi
jehovah
wit
femal
odd
ratio
death
adjust
signific
factor
overal
mortal
rate
studi
confirm
import
clinic
point
low
risk
mortal
patient
hemoglobin
rang
gdl
risk
substanti
increas
lower
hemoglobin
rang
unadjust
odd
ratio
death
per
gdl
decreas
nadir
postop
hgb
ci
although
number
patient
fell
hemoglobin
group
extrem
small
recent
use
technolog
medicin
worldwid
substanti
decreas
risk
side
effect
mani
medic
includ
therapeut
procedur
blood
transfus
observ
studi
evalu
impact
computer
clinic
decis
support
system
see
would
promot
proper
decis
make
strategi
transfus
red
blood
cell
rbc
physician
patient
outcom
overal
mortal
readmiss
length
stay
well
number
rbc
transfus
assess
implement
computer
alert
trigger
transfus
hemoglobin
level
higher
gdl
result
overwhelmingli
posit
signific
improv
rbc
util
clinic
patient
outcom
show
improv
well
mortal
p
length
stay
p
remain
stabl
readmiss
rate
p
mean
number
unit
transfus
per
patient
also
declin
p
also
led
reduct
acquisit
cost
rbc
unit
author
conclud
statist
signific
improv
clinic
patient
outcom
combin
improv
blood
util
protocol
base
computer
clinic
decis
support
system
neutrophil
granulocyt
abund
type
white
blood
cell
human
form
essenti
part
innat
immun
system
form
stem
cell
bone
marrow
neutrophil
play
critic
role
prevent
infect
part
innat
immun
system
reduct
neutrophil
absolut
count
cellspl
term
sever
neutropenia
agranulocytosi
neutrophil
abl
phagocyt
foreign
substanc
bacteria
blood
product
use
patient
function
defect
granulocyt
well
neutropen
patient
lifethreaten
microbi
infect
occasion
transfus
product
associ
hypoxia
secondari
high
concentr
degrad
cell
studi
involv
patient
prolong
neutropenia
suspect
invas
pulmonari
aspergillosi
ia
patient
subdivid
two
treatment
group
group
one
receiv
granulocyt
transfus
antifung
therapi
group
two
receiv
antifung
therapi
patient
receiv
granulocyt
transfus
less
like
respond
antifung
therapi
p
higher
mortal
rate
p
among
patient
receiv
granulocyt
transfus
develop
pulmonari
reaction
character
worsen
short
breath
pulmonari
infiltr
within
hour
receiv
transfus
studi
suggest
granulocyt
transfus
improv
respons
antifung
therapi
associ
wors
outcom
invas
aspergillosi
platelet
transfus
prevent
major
haemorrhag
improv
surviv
thrombocytopen
patient
mani
decad
advanc
prepar
platelet
includ
introduct
pathogen
reduct
techniqu
improv
addit
indic
extend
exampl
patient
druginduc
platelet
dysfunct
howev
platelet
shortag
seriou
medic
concern
novemb
american
associ
blood
bank
publish
guidelin
administr
platelet
transfus
adult
patient
guidelin
includ
one
strong
recommend
moder
qualiti
evid
platelet
could
transfus
prophylact
reduc
risk
spontan
bleed
adult
patient
admit
hospit
platelet
count
cellsl
less
low
dose
equal
effect
high
dose
societi
thorac
surgeon
recommend
patient
transfus
coronari
arteri
bypass
hemoglobin
concentr
fell
less
gl
gdl
time
patient
would
automat
transfus
surgeri
hemoglobin
gl
gdl
due
similar
guidelin
total
number
transfus
year
fall
accord
american
red
cross
cover
us
blood
bank
market
decreas
medic
cost
well
decreas
risk
unnecessari
side
effect
plasma
constitu
implic
sever
type
platelet
plt
transfus
reaction
leukoreduc
apheresi
platelet
store
intersol
less
plasma
apheresi
platelet
store
plasma
pp
openlabel
nonrandom
retrospect
studi
compar
transfus
reaction
rate
intersol
plt
versu
pp
transfus
sever
site
includ
major
transfus
given
patient
apheresi
platelet
store
plasma
pp
total
advers
reaction
report
major
appear
pp
arm
review
properti
hemoglobin
potenti
blood
substitut
discuss
author
offer
direct
link
side
effect
potenti
advers
outcom
could
link
viscos
vessel
wall
stress
nitric
oxid
deliveri
cellfre
purifi
glutaraldehyd
crosslink
polymer
bovin
hemoglobin
compar
red
cell
transfus
noncardiac
surgeri
patient
studi
conduct
antitrypsin
aat
broad
antiinflammatori
immunomodul
properti
administr
human
plasmaderiv
aat
protect
model
acut
myocardi
infarct
mice
object
prospect
openlabel
singlearm
treatment
studi
determin
safeti
toler
human
plasmaderiv
aat
effect
acut
inflammatori
respons
nonaat
defici
patient
stsegment
elev
myocardi
infarct
stemi
ten
patient
acut
stemi
enrol
receiv
aat
mgkg
iv
within
hour
admiss
creactiv
protein
crp
plasma
aat
level
determin
admiss
hour
day
patient
follow
clinic
week
occurr
new
onset
heart
failur
recurr
myocardi
infarct
death
compar
histor
control
area
curv
crp
level
significantli
lower
day
admiss
studi
group
vs
mgl
p
conclus
singl
administr
studi
agent
patient
stemi
well
toler
associ
blunt
acut
inflammatori
respons
hereditari
angioedema
hae
due
esteras
inhibitor
defici
rare
genet
disord
present
recurr
episod
skin
swell
abdomin
pain
potenti
fatal
laryng
edema
observ
studi
design
review
safeti
efficaci
human
plasmaderiv
concentr
treatment
patient
systemat
review
nearli
studi
patient
perform
investig
hae
replac
therapi
significantli
shorten
time
onset
symptom
relief
hae
attack
compar
placebo
mani
review
studi
shown
effect
patient
receiv
home
therapi
shortand
longterm
prophylaxi
treatment
gener
well
toler
administr
associ
transmiss
virus
develop
autoantibodi
irrespect
treatment
durat
anoth
observ
studi
want
get
physician
perspect
thought
true
incid
side
effect
administ
hae
patient
studi
done
via
survey
physician
manag
patient
hae
studi
design
determin
risk
thrombosi
associ
via
survey
survey
queri
physician
observ
treat
hae
physician
particip
survey
patient
patient
total
patient
patient
experienc
thromboembol
episod
anoth
studi
sought
evalu
safeti
escal
dose
cintyz
nonfilt
inhibitor
patient
previous
control
standard
dose
unit
everi
day
elig
patient
hae
attackmonth
dose
escal
went
unit
max
dose
patient
base
continu
number
attack
per
month
eighteen
patient
experienc
common
previous
report
side
effect
four
patient
report
seriou
reaction
includ
cerebr
cystic
hygroma
laryng
angioedema
attack
anemia
bile
duct
stone
effect
consid
investig
unrel
treatment
notabl
system
thrombot
event
discontinu
due
advers
event
dose
escal
nanofilt
inhibitor
human
unit
well
toler
reduc
attack
frequenc
major
patient
cryoprecipit
origin
develop
therapi
patient
antihaemophil
factor
defici
haemophilia
use
nearli
year
product
recombin
purifi
factor
concentr
classic
indic
hemophilia
von
willebrand
diseas
longer
appropri
cryoprecipit
commonli
use
replenish
fibrinogen
level
patient
acquir
coagulopathi
ex
hemorrhag
includ
cardiac
surgeri
trauma
organ
transplant
obstetr
hemorrhag
agent
blood
product
manufactur
fresh
frozen
plasma
contain
subset
coagul
factor
name
fibrinogen
minimum
mg
unit
factor
viii
minimum
iuunit
von
willebrand
factor
factor
xiii
current
cryoprecipit
use
treat
hypofibrinogemia
object
retrospect
noncontrol
observ
studi
determin
safeti
efficaci
cryoprecipit
improv
plasma
fibrinogen
level
coagul
paramet
clinic
statu
acut
chronic
acquir
hypofibrinogenaemia
averag
fibrinogen
level
administr
cryoprecipit
similar
two
diseas
group
acut
vs
chronic
amount
cryoprecipit
administ
compar
two
cohort
hour
postcryoprecipit
mean
fibrinogen
level
higher
acut
group
compar
chronic
group
vs
gl
p
despit
cohort
differ
increas
fibrinogen
level
statist
signific
cohort
baselin
hour
acut
p
chronic
p
anoth
import
note
acut
advers
transfus
reaction
report
direct
result
cryoprecipit
administr
case
transfusionassoci
circulatori
overload
taco
transfusiontransmit
infect
tti
note
indic
cryoprecipit
effect
safe
method
increas
plasma
fibrinogen
level
hypofibrinogenaem
patient
retrospect
analysi
perform
identifi
frequenc
advers
reaction
transfus
per
transfus
patient
per
transfus
unit
basi
studi
evalu
red
blood
cell
rbc
fresh
frozen
plasma
ffp
platelet
concentr
pc
incid
advers
reaction
rbc
ffp
pc
per
transfus
unit
respect
incid
advers
reaction
rbc
ffp
pc
per
patient
respectivelyalmost
threefold
higher
rbc
associ
advers
reaction
febril
nonhemolyt
transfus
reaction
allerg
reaction
wherea
ffp
pc
associ
advers
reaction
allerg
reaction
consist
found
prior
literatur
crystalloid
versu
colloid
resuscit
includ
use
he
subject
sever
systemat
review
one
analysi
includ
two
studi
compar
starch
albumin
sepsi
found
albumin
associ
decreas
risk
mortal
ci
moder
qualiti
evid
comparison
starch
gelatin
crystalloid
statist
signific
administr
ml
he
ml
ringer
lactat
rl
compar
ml
rl
healthi
mother
elect
caesarian
section
spinal
anesthesia
use
he
rl
associ
lower
incid
hypotens
compar
p
pure
rl
group
differ
phenylephrin
requir
postop
matern
hemoglobin
neonat
outcom
he
concentr
undetect
umbil
cord
sampl
obtain
six
neonat
assign
he
group
administr
he
volum
replac
studi
pediatr
open
heart
surgeri
patient
result
less
posit
fluid
balanc
patient
treat
albumin
p
coagul
compet
measur
thrombolastographi
periop
blood
loss
compar
patient
undergo
cystectomi
administ
mlkg
he
rl
reduc
develop
strength
clot
patient
treat
he
periop
blood
loss
ml
he
group
compar
ml
group
treat
rl
p
similar
comparison
cardiac
surgeri
patient
receiv
he
albumin
rl
major
periop
fluid
maxim
dose
mlkgday
differ
volum
chest
tube
drainag
howev
patient
treat
he
requir
transfus
compar
patient
treat
albumin
rl
respect
pvalu
he
vs
post
hoc
analysi
scandinavian
starch
sepsi
databas
he
administr
associ
increas
risk
bleed
compar
ringer
acet
rr
ci
also
associ
increas
risk
death
rr
ci
role
he
develop
renal
dysfunct
explor
recent
review
surgic
popul
one
studi
onpump
cardiac
bypass
surgeri
patient
compar
normal
salin
he
resuscit
dose
mlkg
minut
start
anesthesia
differ
rate
acut
kidney
injuri
group
howev
anoth
metaanalysi
studi
patient
sepsi
rate
acut
kidney
injuri
requir
renal
replac
therapi
higher
treatment
he
differ
icu
mortal
increas
rate
mortal
patient
treat
he
compar
crystalloid
crystalloid
versu
colloid
resuscit
includ
use
gelatin
subject
systemat
review
gelatin
compar
starch
one
studi
includ
metaanalysi
differ
mortal
sepsi
resuscit
note
mechan
immunoglobulin
primari
secondari
immunodefici
disord
deliveri
matur
antibiot
adequ
concentr
varieti
pathogen
mechan
action
condit
less
understood
antiinflammatori
immunomodul
effect
present
varieti
intraven
immunoglobulin
ivig
product
avail
differ
studi
indic
formul
potenti
toxic
volum
load
sugar
content
osmolar
sodium
content
iga
content
ph
prepar
influenc
potenti
reaction
varieti
advers
reaction
manag
strategi
relat
intraven
immunoglobulin
ivig
infus
reaction
headach
nausea
vomit
musculoskelet
pain
flush
tachycardia
mani
prevent
premed
use
nsaid
corticosteroid
antihistamin
acetaminophen
anaphylactoid
reaction
appear
like
anaphylaxi
differenti
due
lack
hypotens
releas
ige
anaphylaxi
due
iga
ivig
product
also
occur
thromboembol
event
follow
treatment
ivig
associ
patient
specif
risk
factor
formul
contamin
coagul
factor
xi
xia
xiia
kallikrein
acut
renal
dysfunct
link
age
diabet
sepsi
concomit
nephrotox
agent
product
contain
sucros
prehydr
employ
decreas
chanc
toxic
hematolog
advers
event
includ
neutropenia
hemolysi
describ
well
seri
propos
european
consensu
statement
publish
follow
kreuth
iii
meet
singl
center
retrospect
review
patient
treat
ivig
period
demonstr
advers
event
rate
patient
popul
common
report
advers
event
fever
follow
rash
onset
fever
frequent
observ
minut
hour
initi
infus
prospect
cohort
infus
ivig
patient
primari
immunodefici
brazil
analyz
advers
event
incid
reaction
infus
patient
pretreat
infus
rate
number
batch
found
significantli
associ
increas
decreas
infus
reaction
reaction
sever
signific
find
respect
latenc
reaction
higher
incid
reaction
tegelin
compar
octagam
neonat
synthesi
immunoglobulin
occur
sever
month
birth
transfer
materi
immunoglobulin
occur
week
gestat
administr
exogen
ivig
neonat
suspect
sepsi
hypothes
reduc
morbid
mortal
cochran
review
studi
infant
mortal
improv
patient
treat
ivig
rr
ci
differ
morbid
year
length
stay
report
similar
review
adult
patient
sepsi
sever
sepsi
review
polyclon
ivig
igmenrich
polyclon
ivig
separ
trial
polyclon
ivig
trial
patient
reduct
mortal
confirm
compar
placebo
rr
ci
seven
trial
patient
treat
igmenrich
polyclon
ivig
reduct
mortal
also
report
rr
ci
howev
studi
low
bia
mortal
reduct
demonstr
cochran
review
seven
trial
patient
guillainbarr
syndrom
improv
differ
compar
control
treatment
mean
chang
valid
disabl
scale
differ
advers
effect
patient
treat
ivig
plasma
exchang
patient
complet
ivig
treatment
incid
thromboembol
event
retrospect
cohort
patient
ci
studi
review
patient
tertiari
care
center
madrid
period
outcom
fatal
thromboembol
event
observ
patient
total
thromboembol
case
patient
experienc
thromboembol
event
tend
older
male
gender
treat
higher
dose
ivig
p
hemolyt
anemia
character
studi
de
novo
mainten
patient
treat
neurolog
condit
fall
hemoglobin
mm
de
novo
mainten
group
respect
signific
chang
reticulocyt
haptoglobin
bilirubin
lactat
dehydrogenas
significantli
increas
case
report
sever
antibodi
mediat
reject
follow
ivig
bk
viru
nephropathi
caucasian
femal
recipi
deceas
donor
transplant
discuss
donor
specif
antibodi
present
prior
ivig
infus
nephrectomi
perform
antibodi
present
follow
ivig
infus
donor
specif
antibodi
hla
hla
present
recipi
serum
twentyf
day
nephrectomi
serum
neg
donor
specif
antibodi
erythemat
rash
palm
chest
describ
recipi
ivig
prospect
studi
patient
receiv
ivig
primari
antibodi
defici
test
plasma
sampl
drug
lot
differ
ivig
product
antibodi
tetanu
diphtheria
measl
varicella
signific
differ
product
drug
lot
ivig
respect
antibodi
diseas
fluctuat
patient
plasma
antibodi
titer
four
blood
sampl
drawn
everi
month
ivig
formul
often
implic
renal
toxic
osmot
nephrosi
associ
glucos
solut
maltos
solut
degrad
brush
boarder
proxim
tubul
therefor
also
implic
nephrotox
mannitol
ivig
excipi
suspect
caus
renal
vasoconstrict
osmot
nephrosi
final
dsorbitol
glycin
lprolin
ivig
product
littl
associ
nephrotox
prospect
openlabel
multicent
studi
adult
pediatr
japanes
patient
primari
immunodefici
assess
serum
igg
trough
level
ivig
treatment
hizentra
lprolin
stabil
human
subcutan
ig
patient
treat
three
mandatori
ivig
infus
follow
washout
period
convers
follow
studi
period
dose
equival
establish
primari
efficaci
endpoint
subcutan
ig
scig
period
patient
experienc
seriou
bacteri
infect
one
patient
requir
hospit
overal
advers
event
rate
per
treatment
scig
ivig
respect
local
infus
site
reaction
occur
patient
scig
treatment
decreas
incid
time
skin
two
patient
describ
necrot
skin
ulcer
site
scig
infus
boy
treat
scig
common
variabl
immunodefici
year
local
erythema
site
inject
patient
experienc
blister
necrot
center
thigh
grew
oxacillinsensit
staphylococcu
aureu
treat
trimethoprimsulfamethoxazol
erythromycin
second
patient
girl
treat
trichothiodystrophi
associ
hypogammaglobulinemia
year
treatment
blister
site
infus
develop
cm
area
indur
cm
necrot
center
hospit
treat
initi
clindamycin
fluconazol
piperacillintazobactam
resolut
infect
day
antibiot
treatment
one
month
scig
treatment
develop
blister
inject
site
treat
clindamycin
develop
necrosi
skin
british
committe
standard
hematolog
bcsh
publish
guidelin
use
antid
immunoglobulin
prevent
hemolysi
newborn
fetus
statement
review
indic
dosag
administr
monitor
low
incid
advers
event
emphas
recommend
surveil
sever
hypersensit
reaction
singl
center
studi
compar
pediatr
patient
treat
immun
thrombocytopenia
march
fda
warn
regard
treatment
antid
immunoglobulin
demonstr
statist
differ
advers
effect
headach
nausea
vomit
hematuria
anemia
fever
chill
frequent
report
advers
event
patient
patient
warn
retrospect
analysi
leukocyt
antibodi
preval
studi
databas
previous
pregnant
rhd
neg
posit
women
compar
hla
sensit
rate
lower
rhd
neg
women
less
equal
year
old
rr
ci
author
conclud
effect
associ
routin
use
rhig
prophylaxi
suspect
hypersensit
reaction
antid
immunoglobulin
three
pregnant
women
describ
primigravida
rh
woman
develop
wheez
sever
dyspnea
periorbit
edema
within
minut
administr
antid
iu
rhophylac
csl
behr
hayward
health
uk
upon
subsequ
pregnanc
skin
prick
intraderm
test
neg
empir
protocol
use
total
iu
rhophylac
administ
subsequ
rh
pregnanc
women
rh
primigravida
administ
iu
rhophylac
week
mcg
dgam
antid
bio
product
laboratori
elstre
uk
upon
deliveri
upon
develop
matern
hemorrhag
iu
rhophylac
administ
minut
hour
patient
develop
tremor
tachycardia
dyspnea
desatur
room
air
month
skin
prick
test
intraderm
test
challeng
iu
rhophylac
elicit
reaction
rh
r
femal
receiv
three
separ
dose
antid
immunoglobulin
first
dose
ic
dgame
felt
unwel
next
receiv
iu
rhophylac
report
lightheaded
blur
vision
facial
edema
pruritu
skin
prick
test
intraderm
test
neg
month
later
iu
rhophylac
becam
dizzi
headach
ocular
pruritu
addit
iu
full
dose
well
toler
report
reaction
risk
inadequ
respons
live
vaccin
influenza
mmr
vaccin
administ
antid
immunoglobulin
obstetr
popul
risk
coadministr
product
remind
patient
followup
vaccin
titer
subject
nurs
qualiti
initi
factor
fibrinogen
factor
concentr
may
either
plasmaderiv
recombin
product
final
protein
common
coagul
cascad
systemat
review
identifi
articl
report
fibrinogen
concentr
fc
usag
trauma
patient
case
report
retrospect
studi
prospect
observ
studi
evalu
avail
studi
suggest
fc
administr
associ
reduc
blood
product
requir
minim
report
advers
event
author
research
studi
hypothes
fast
time
coagul
test
standard
decreas
patient
safeti
studi
evalu
impact
whether
light
meal
ie
breakfast
jeopard
laboratori
coagul
test
blood
sampl
first
collect
fast
volunt
fast
immedi
blood
collect
volunt
consum
light
meal
sampl
collect
hour
light
meal
sever
coagul
test
evalu
includ
fibrinogen
fbg
level
result
fbg
ps
test
influenc
light
meal
author
conclud
light
meal
influenc
laboratori
coagul
test
suggest
laboratori
qualiti
manag
standard
fast
time
blood
test
hour
complet
metabol
lipid
intak
wide
varieti
topic
agent
approv
potenti
therapi
mainten
hemostasi
surgic
procedur
multidisciplinari
approach
select
applic
agent
requir
input
member
surgic
team
topic
thrombin
may
either
bovin
recombin
sourc
thrombin
play
central
role
coagul
activ
platelet
cleav
fibrinogen
often
use
intraop
hemorrhag
control
may
also
use
superfici
wound
sever
bleed
defin
loss
total
blood
volum
associ
markedli
increas
risk
morbid
mortal
sever
postpartum
hemorrhag
refractori
standard
treatment
use
rfviia
consid
even
though
case
report
suggest
potenti
benefit
agent
clinic
set
lack
random
control
trial
greatli
limit
valu
avail
favor
data
recent
report
publish
world
health
organ
recommend
prevent
treatment
postpartum
hemorrhag
group
conclud
insuffici
evid
recommend
rfviia
treatment
postpartum
hemorrhag
use
limit
women
licens
hematolog
indic
group
regard
rfviia
potenti
lifesav
drug
note
also
associ
lifethreaten
advers
effect
post
hoc
analysi
assess
safeti
rfviia
dose
congenit
haemophilia
impact
dose
total
rfviia
dose
report
patient
treat
bleed
event
half
exceed
exceed
exceed
anoth
studi
evalu
longterm
safeti
efficaci
factor
ix
gene
therapi
hemophilia
b
patient
gene
therapi
mediat
novel
adenoassoci
viru
serotyp
vector
shown
rais
factor
ix
level
author
sought
evalu
patient
sever
hemophilia
b
benefit
gene
therapi
rais
factor
ix
level
decreas
rate
bleed
effect
found
clinic
posit
signific
decreas
rate
acut
bleed
episod
report
acut
late
toxic
effect
prothrombin
complex
concentr
seda
three
main
type
prothrombin
complex
concentr
pcc
avail
market
worldwid
first
one
activatedpcc
contain
activ
form
factor
ii
vii
ix
x
activ
pcc
use
bypass
therapi
hemophilia
patient
develop
inhibitor
antibodi
second
type
fourfactor
pcc
contain
nonactiv
form
factor
ii
vii
ix
x
final
threefactor
pcc
contain
nonactiv
form
factor
ii
ix
x
lack
factor
vii
threeand
fourfactor
nonactiv
pcc
often
use
anticoagul
revers
sever
hemorrhag
clinic
practic
twentyf
patient
underw
cardiac
surgeri
coagulopathi
lifethreaten
bleed
refractori
convent
treatment
receiv
activ
prothrombin
complex
concentr
feiba
factor
viii
inhibitor
bypass
activ
mean
feiba
dose
unit
need
fresh
frozen
plasma
platelet
transfus
decreas
significantli
feiba
administr
p
p
respect
mean
internation
normal
ratio
decreas
p
studi
investig
report
clinic
outcom
excel
patient
return
oper
room
reexplor
hospit
mortal
patient
discharg
home
pcc
use
revers
option
warfarin
anticoagul
studi
compar
warfarin
revers
patient
receiv
either
threefactor
pcc
lowdos
rfviia
ldrfviia
revers
warfarin
anticoagul
seventyfour
ldrfviia
patient
analyz
baselin
demograph
reason
warfarin
revers
initi
inr
equival
differ
number
thromboembol
event
ldrfviia
vs
p
mortal
length
hospit
stay
cost
similar
result
found
studi
spain
evalu
use
pcc
revers
vitamin
k
antagonist
studi
report
infus
reaction
detect
thrombot
episod
observ
patient
includ
studi
anoth
studi
sought
evalu
safeti
efficaci
nonactiv
fourfactor
pcc
versu
plasma
patient
experienc
major
bleed
take
vitamin
k
antagonist
outcom
clinic
statist
posit
favor
use
fourfactor
pcc
safeti
profil
similar
group
group
studi
immun
toler
induct
iti
therapi
haemophilia
patient
focus
primari
iti
children
author
studi
report
iti
outcom
larg
retrospect
cohort
includ
adult
patient
rescu
iti
treat
pdfviiivwf
concentr
success
rate
achiev
primari
iti
higher
risk
profil
rescu
iti
sever
safeti
concern
observ
includ
venou
access
complic
consist
seven
infect
one
case
haemarthrosi
bleed
joint
space
one
case
allergi
pdfviiivwf
concentr
consid
failur
therapi
one
case
pleural
haemorrhag
resolv
treatment
safeti
recombin
von
willebrand
factor
rvwf
combin
fix
ratio
recombin
factor
viii
rfviii
investig
subject
von
willebrand
diseas
vwd
prospect
phase
multicent
random
clinic
trial
author
conclud
rvwf
well
toler
thrombot
event
seriou
advers
event
note
erythropoiesisstimul
agent
often
use
attenu
blood
transfus
among
anem
patient
receiv
chemotherapi
chronic
kidney
diseas
ckd
howev
agent
without
potenti
seriou
side
effect
shown
associ
venou
thromboembol
increas
mortal
reason
recent
cochran
review
discuss
potenti
advers
effect
agent
use
set
ckd
clinic
guidelin
recommend
esa
treatment
avoid
blood
transfus
anemiarel
symptom
patient
ckd
howev
whether
avail
esa
equal
effect
safe
adequ
evalu
individu
rct
data
effect
esa
treatment
compar
placebo
treatment
allcaus
mortal
provid
studi
involv
particip
three
agent
epoetin
alfa
epoetin
beta
darbepoetin
alfa
assess
placebo
treatment
patient
underli
ckd
odd
allcaus
mortal
cardiovascular
mortal
mi
statist
signific
three
agent
howev
consid
odd
stroke
result
statist
signific
epoetin
alfa
beta
group
increas
darbepoetin
alfa
group
compar
placebo
similar
result
found
hypertens
three
agent
higher
propens
increas
blood
pressur
comparison
placebo
openlabel
extens
trial
eltrombopag
japanes
patient
chronic
immun
thrombocytopenia
itp
follow
patient
drug
commerci
avail
seriou
advers
event
occur
median
durat
therapi
month
patient
treat
year
concomit
treatment
requir
n
patient
patient
treat
corticosteroid
advers
event
includ
nasopharyng
headach
two
event
chest
pain
normal
ecg
determin
associ
eltrombopag
four
event
cataract
progress
report
three
patient
treatment
two
consid
seriou
advers
event
relat
treatment
five
patient
experienc
elev
liver
enzym
total
bone
marrow
biopsi
obtain
patient
normal
show
grade
bone
marrow
fibrosi
sixti
six
patient
treat
tpo
follow
median
month
treatment
begin
treatment
bone
marrow
biopsi
show
fibrosi
decreas
end
treatment
high
grade
myelofibrosi
either
associ
older
age
grade
myelofibrosi
associ
initi
marrow
grade
tpo
dose
tpo
agent
immatur
platelet
fraction
eltrombopaginduc
hyperpigment
skin
describ
two
patient
tissu
biopsi
fontanamasson
stain
prussian
blue
stain
posit
demonstr
increas
melatonin
deposit
hemosiderin
deposit
red
blood
cell
leakag
respect
romiplostim
use
two
pregnant
patient
steroid
resist
immun
thrombocytopenia
week
gestat
neonat
complic
report
serum
patient
treat
eltrombopag
appear
dark
reddish
brown
alter
base
drug
concentr
ph
erron
result
serum
total
bilirubin
describ
patient
treat
eltrombopag
borrelia
burgdorferi
transmiss
transfus
wide
describ
author
postul
due
low
bacteri
low
infect
human
inabl
hostadapt
spirochet
surviv
blood
storag
condit
risk
arboviru
southeast
asia
emerg
due
limit
resourc
high
incid
infect
french
polynesia
outbreak
zika
viru
test
asymptomat
blood
donor
carri
three
percent
donor
zika
viru
posit
use
pcr
test
transmiss
hepat
c
viru
antihcv
neg
donor
two
recipi
turkey
describ
donor
woman
found
hcvrna
viru
antihcv
posit
week
donat
initi
donat
blood
test
hcvrna
viral
load
iuml
two
recipi
diagnos
hepat
c
viru
one
recipi
femal
receiv
red
blood
cell
hemoglobin
gdl
success
treat
interferon
alpha
recipi
male
myeloid
leukemia
receiv
platelet
treat
hepat
c
viru
due
comorbid
diseas
author
highlight
need
nucleic
acid
amplif
test
donor
decreas
risk
endocrinolog
one
center
patient
histori
diabet
vari
diabet
complic
administ
autolog
stem
cell
observ
chang
therapi
improv
symptom
level
hour
urin
protein
quantiti
research
report
clinic
improv
hemoglobin
level
hour
urin
protein
quantiti
toxic
side
effect
literatur
suggest
hematopoiet
stem
cell
transplant
hsct
associ
respiratori
infect
due
immunosuppress
retrospect
trial
research
aim
investig
frequenc
rhinosinus
hsct
associ
rhinosinus
chronic
graft
vs
host
diseas
gvhd
patient
gvhd
higher
frequenc
recurr
rhinosinus
addit
frequent
need
endoscop
sinusectomi
decreas
overal
surviv
hematopoiet
cell
transplant
hct
accept
treatment
mani
malign
disord
may
side
effect
sever
major
organ
includ
cardiovascular
system
studi
cardiac
function
evalu
use
echocardiographi
level
ntprobnp
patient
match
control
patient
hct
group
cardiac
dimens
left
ventricular
eject
fraction
within
normal
rang
howev
also
lower
measur
left
ventricular
diastol
function
significantli
higher
ntprobnp
level
investig
also
report
heart
rate
significantli
higher
hct
group
